Champions Oncology (FRA:2I3) EV-to-EBITDA : -9.68 (As of Jun. 05, 2024)

Champions Oncology EV-to-EBITDA Chart

Champions Oncology Annual Data
	Trend	Apr14	Apr15	Apr16	Apr17	Apr18	Apr19	Apr20	Apr21	Apr22	Apr23
EV-to-EBITDA		Get a 7-Day Free Trial					116.76	-123.14	96.03	46.69	-29.56

Champions Oncology Quarterly Data
	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24
EV-to-EBITDA	Get a 7-Day Free Trial															-64.97	-29.56	-20.01	-11.64	-12.09

Competitive Comparison of Champions Oncology's EV-to-EBITDA

For the Biotechnology subindustry, Champions Oncology's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Champions Oncology's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Champions Oncology's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Champions Oncology's EV-to-EBITDA falls into.

Champions Oncology EV-to-EBITDA Calculation

Champions Oncology's EV-to-EBITDA for today is calculated as:

Champions Oncology's current Enterprise Value is €60.53 Mil.
Champions Oncology's EBITDA for the trailing twelve months (TTM) ended in Jan. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-6.25 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Champions Oncology  (FRA:2I3) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Champions Oncology's PE Ratio for today is calculated as:

Champions Oncology's share price for today is €4.32.
Champions Oncology's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jan. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.661.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?

Champions Oncology EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Champions Oncology's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Champions Oncology (FRA:2I3) Business Description